LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy

Area of Science:

• Oncology
• Immunology
• Radiotherapy

Background:

• Immunotherapy combined with radiotherapy shows synergistic potential, particularly with immune checkpoint inhibitors (ICIs).
• Radiotherapy enhances immunomodulatory effects, akin to in situ vaccination and abscopal responses.
• Emerging targets like TIGIT, LAG-3, and TIM-3 expand the scope of immuno-radiotherapy.

Purpose of the Study:

• To explore the synergistic potential of combining immunotherapy, including novel immune checkpoint inhibitors, with radiotherapy.
• To investigate the immunomodulatory mechanisms activated by the combination of radiotherapy and ICIs.
• To assess the potential of T lymphocyte expression as a biomarker for combination therapy response.

Main Methods:

• Review of preclinical and clinical studies on immunotherapy and radiotherapy combinations.
• Analysis of immunomodulatory mechanisms, including in situ vaccination and abscopal effects.
• Evaluation of novel therapeutic targets (TIGIT, LAG-3, TIM-3) in immuno-radiotherapy.

Main Results:

• Combination therapy with ICIs and radiotherapy demonstrates synergistic anti-tumor effects.
• Radiotherapy induces beneficial immune responses, enhancing immunotherapy efficacy.
• Dynamic evaluation of T lymphocyte expression in the tumor microenvironment may serve as a predictive biomarker.

Conclusions:

• Immuno-radiotherapy, incorporating traditional and novel ICIs with radiotherapy, presents promising therapeutic strategies.
• Further clinical trials are warranted to explore the efficacy of these combinations across various tumor types.
• Biomarker strategies focusing on T lymphocyte dynamics are crucial for optimizing treatment response assessment.